

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



LSHTM Research Online

Aniweh, Yaw; Nyarko, Prince B; Charles-Chess, Essel; Ansah, Felix; Osier, Faith HA; Quansah, Evelyn; Thiam, Laly Gaye; Kamuyu, Gathoni; Marsh, Kevin; Conway, David J; +2 more... Tetteh, Kevin KA; Awandare, Gordon A; (2020) Plasmodium falciparum Merozoite Associated Armadillo Protein (PfMAAP) Is Apically Localized in Free Merozoites and Antibodies Are Associated With Reduced Risk of Malaria. *Frontiers in Immunology*, 11. p. 505. DOI: <https://doi.org/10.3389/fimmu.2020.00505>

Downloaded from: <http://researchonline.lshtm.ac.uk/id/eprint/4656638/>

DOI: <https://doi.org/10.3389/fimmu.2020.00505>

**Usage Guidelines:**

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by/2.5/>

<https://researchonline.lshtm.ac.uk>



# *Plasmodium falciparum* Merozoite Associated Armadillo Protein (PfMAAP) Is Apically Localized in Free Merozoites and Antibodies Are Associated With Reduced Risk of Malaria

Yaw Aniweh<sup>1\*</sup>, Prince B. Nyarko<sup>1,2</sup>, Essel Charles-Chess<sup>1,2</sup>, Felix Ansah<sup>1,2</sup>, Faith H. A. Osier<sup>3,4,5,6</sup>, Evelyn Quansah<sup>1,2</sup>, Laty Gaye Thiam<sup>1,2</sup>, Gathoni Kamuyu<sup>7</sup>, Kevin Marsh<sup>3,6,8</sup>, David J. Conway<sup>9</sup>, Kevin K. A. Tetteh<sup>9\*</sup> and Gordon A. Awandare<sup>1,2\*</sup>

## OPEN ACCESS

### Edited by:

Daniel M. Altmann,  
Imperial College London,  
United Kingdom

### Reviewed by:

Danny Wilson,  
University of Adelaide, Australia  
Lloyd King,  
University of Oxford, United Kingdom

### \*Correspondence:

Yaw Aniweh  
yaniweh@ug.edu.gh  
Kevin K. A. Tetteh  
Kevin.Tetteh@lshtm.ac.uk  
Gordon A. Awandare  
gawandare@ug.edu.gh

### Specialty section:

This article was submitted to  
Microbial Immunology,  
a section of the journal  
Frontiers in Immunology

**Received:** 14 June 2019

**Accepted:** 05 March 2020

**Published:** 07 April 2020

### Citation:

Aniweh Y, Nyarko PB, Charles-Chess E, Ansah F, Osier FHA, Quansah E, Thiam LG, Kamuyu G, Marsh K, Conway DJ, Tetteh KKA and Awandare GA (2020) *Plasmodium falciparum* Merozoite Associated Armadillo Protein (PfMAAP) Is Apically Localized in Free Merozoites and Antibodies Are Associated With Reduced Risk of Malaria. *Front. Immunol.* 11:505. doi: 10.3389/fimmu.2020.00505

<sup>1</sup> West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Accra, Ghana, <sup>2</sup> Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana, <sup>3</sup> KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya, <sup>4</sup> Centre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg, Germany, <sup>5</sup> Department of Biochemistry, Pwani University, Kilifi, Kenya, <sup>6</sup> Nuffield Department of Clinical Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom, <sup>7</sup> Division of Medicine, Department of Respiratory Medicine, UCL, London, United Kingdom, <sup>8</sup> Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, <sup>9</sup> Department of Infection Biology, London School of Tropical Medicine and Hygiene, London, United Kingdom

Understanding the functional role of proteins expressed by *Plasmodium falciparum* is an important step toward unlocking potential targets for the development of therapeutic or diagnostic interventions. The armadillo (ARM) repeat protein superfamily is associated with varied functions across the eukaryotes. Therefore, it is important to understand the role of members of this protein family in *Plasmodium* biology. The *Plasmodium falciparum* armadillo repeats only (PfARO; Pf3D7\_0414900) and *P. falciparum* merozoite organizing proteins (PfMOP; Pf3D7\_0917000) are armadillo-repeat containing proteins previously characterized in *P. falciparum*. Here, we describe the characterization of another ARM repeat-containing protein in *P. falciparum*, which we have named the *P. falciparum* Merozoites-Associated Armadillo repeats protein (PfMAAP). Antibodies raised to three different synthetic peptides of PfMAAP show apical staining of free merozoites and those within the mature infected schizont. We also demonstrate that the antibodies raised to the PfMAAP peptides inhibited invasion of erythrocytes by merozoites from different parasite isolates. In addition, naturally acquired human antibodies to the N- and C- termini of PfMAAP are associated with a reduced risk of malaria in a prospective cohort analysis.

**Keywords:** Malaria, armadillo, invasion, merozoites, antigen, antibodies, recombinant protein

## INTRODUCTION

Human malaria is caused by several species of the genus *Plasmodium*, with the majority of deaths attributed to *Plasmodium falciparum*. The life cycle of the parasite is multifaceted involving both the mosquito vector and the human host, with asexual multiplication of the parasite in the blood responsible for the clinical manifestations of the disease. Asexual replication requires successful

invasion of the erythrocyte by the merozoite stage. This process is complex, involving proteins released from the apical organelles or located on the merozoite surface (1, 2).

Proteins stored in organelles such as the micronemes, rhoptries, and dense granules have been extensively studied to define their roles in merozoite invasion (1, 2). Notable invasion-linked protein families include the *P. falciparum* reticulocyte binding like protein homologs (PfRH1, 2a, 2b, 4, and 5) (3–8), the erythrocyte binding antigens (PfEBAs; EBA 140, 175, 181 & EBL1) (9–14) and the rhoptry neck proteins (RONs) (15, 16). Other proteins such as AMA1 (17) have been shown to play critical roles during the process of merozoite invasion.

Our interest in the PF3D7\_1035900 protein arose from a survey of the antigen-rich chromosome 10 cluster. A region that contains a number of well-characterized putative vaccine candidates including, the MSP3/6 protein family (18, 19), GLURP (20, 21), liver stage antigen 1 (22), to name but a few. In addition to its location, transcriptional data demonstrated a peak of expression at the late schizont/early merozoite stage (23, 24), a profile that hinted at a biological importance for the late schizont and merozoite stages of the parasite.

To understand the role this gene played in parasite biology our initial investigations determined that PF3D7\_1035900 was a member of the armadillo protein family, a family with pleiotropic functions that warranted further investigation as a potential intervention target. The eukaryotic armadillo repeat proteins are involved in diverse roles including cell adhesion, cell motility, cytoskeletal arrangement, molecular chaperones, cell signaling/sensing, and nuclear import (25, 26). In apicomplexan parasites, the armadillo repeat containing proteins are being characterized for their role during parasite development. The importance of this protein family is highlighted by their involvement in fundamental processes essential to parasite biology, including but not restricted to gene regulation and cytokinesis. Essential processes have been linked with the previously described *P. falciparum* ARM Repeats Only (PfARO) and *P. falciparum* Merozoite Organizing Proteins (PfMOP) (22), respectively. The putative function of PfARO has been assigned through studies using the *Toxoplasma gondii* paralog, TgARO (20, 21). In this study, we describe the characterization of another member of the armadillo repeat family of proteins, encoded by gene locus PF3D7\_1035900, which lies in an antigenic rich region of chromosome 10 among members of the *msp3* gene family and several other antigen genes.

The gene shows peak expression late in the developmental cycle in the schizont. Antibodies raised to synthetic peptides demonstrate staining of the apical tip in free merozoites and those within the schizont. We propose the name *Plasmodium falciparum* merozoite associated armadillo protein (PfMAAP) due to its association with fully segmented merozoites within the mature schizont and with free merozoites. Furthermore, we show that the recombinant proteins based on the N-, central repeat and C- terminal regions are recognized by antibodies in plasma of malaria exposed individuals, with antibodies to the N and C- terminal conserved domains being associated with a lower prospective risk of contracting malaria.

## RESULTS


### PfMAAP Is an Armadillo (ARM)-Repeat Containing Protein

To determine the putative function of the PfMAAP protein (PF3D7\_1035900) we interrogated the amino acid sequence to gain insight into the protein product. Aside from a signal peptide (amino acid 1 to 21; **Figure 1A**), we identified an armadillo (ARM)-repeat domain comprised of 5 repeats (aa 144–504; **Figures 1A,B**) and an overlapping Pumilio homolog domain (aa 202–566; **Figure 1A**). We analyzed the amino acid sequences for 16 isolates using the REPEATS and their PERIODICITIES (REPPER) server (<https://toolkit.tuebingen.mpg.de/#/tools/repper>), which identifies short gapless repeats in both protein and nucleotide sequences (27). Both the laboratory and field isolates showed that the central repeat region always started at amino acid position 144 but varied in length from 166 (7G8 isolate) to 467 (GB4 isolate) amino acids (**Figure S1** and **Table S1**). Amino acid sequence alignments also showed high levels of sequence conservation within the *P. falciparum* isolates (**Figure S1**) and between *P. falciparum* (3D7) and available sequences for non-human primate malarias at both the N- and C-terminal regions (**Figure S2**). The position of the repeat regions in all isolates was validated using the REPPER server (27, 28) (**Figure S3** and **Tables S1, S2**). Further investigation of the PfMAAP protein was performed by *in silico* structural modeling using the I-Tasser structural prediction server (29–31). This was done to determine the putative structure of the proteins and to identify structural, and potentially functional, homologs of the PfMAAP protein. Using the I-Tasser structural prediction algorithm, the resolved crystal structures for three armadillo-repeat containing proteins, showing close structural homology with the PfMAAP protein were identified (**Figure 1B**). These include,  $\beta$ -catenin, a molecule shown to be involved in cadherin-based adhesion and implicated in cerebral malaria (27, 29, 30); the symmetrical sisters (SYS)-1 protein, functionally similar to  $\beta$ -catenin (32); and Plakophilin 1, also functionally similar to  $\beta$ -catenin (**Figure 1B**). All of these which provides additional evidence of as to the potential biological significance of the PfMAAP protein.

The PfMAAP region was also identified in the available *Plasmodium* sequences from 6 *Laverania* species infections of primates (**Figure S2**), suggesting an ancient origin for the protein family. Using the 3D7 isolate as the reference sequence, we show that the signal peptide and an additional 100 amino acids (position 22–121) have high levels of sequence identity between the human (3D7) and *Laverania* primate species at the N- and C-terminal regions (**Figure S2**). However, the repeat regions varied extensively in the composition of the repeats, ranging from 190 to 402 aa in length (**Figure S2** and **Table S2**).

### PfMAAP Is Expressed Late in Erythrocytic Stage Development

Transcript expression analysis of three *P. falciparum* laboratory-adapted strains (3D7, W2mef, Dd2) were performed across the asexual blood stage cycle at 8-h intervals. The expression levels were evaluated in triplicate and were the results of two separate




experiments. The transcript expression profile demonstrated that expression of *PfMAAP* peaked in the later stages of parasite development at around 40–48 h post invasion (**Figure 1C**). This finding was supported by transcript data previously reported on Plasmodb (<https://plasmodb.org/plasmo/>) and in (24, 32).

## **PfMAAP Is Expressed in Both Merozoites and Schizonts**

Three peptides spanning 14 amino acids, located at the C- (*PfMAAP1*) and N-terminal (*PfMAAP2* and 3) regions (**Figure 1A**) were used to immunize three rabbits per group. The polyclonal sera obtained was then used to identify the location of the expressed gene product by immunofluorescence assay and thereby validate the presence of native epitopes within the peptides by recognition of the native parasite protein. Antibodies raised to all three peptides showed localization of the native protein by immunofluorescence assay (IFA) on free merozoites and those located within fixed preparations of mature schizonts (**Figures 2A–C**). All three antibody preparations showed similar staining patterns within mature schizonts and free merozoites (**Figures 2A–C** and **Figure S4**). As a result, all subsequent IFA experiments will simply be referred to as  $\alpha$ -*PfMAAP* antibody. The staining patterns observed showed a clear merozoite surface staining pattern in developing schizonts and a predominantly apical staining in free merozoites and on those within mature rupturing schizonts (**Figure 2A**). The staining pattern was compared by co-localization with relative to *PFAMA1* (micronemes), *PfRAP2* (rhoptry bulb), and *PfRON4* (rhoptry neck) (**Figures 2A–C**). Co-localization with  $\alpha$ -*AMA1* antibodies (a micronemal marker), showed apical staining of merozoites within the mature schizont (**Figure 2A**) and on free merozoites (**Figure 2B**), with a small proportion showing diffuse surface staining of the merozoite by the  $\alpha$ -*PfMAAP* antibody (**Figure 2A**, top panel). Punctate apical staining was also observed with co-localization of the  $\alpha$ -*PfMAAP* with the  $\alpha$ -*PfRAP2* (a marker for the rhoptry bulb) and  $\alpha$ -*PfRON4* (a rhoptry neck marker) (**Figures 2A,B**); although in the latter two cases, no additional peri-merozoite staining was observed. To clarify the merozoite surface-like staining observed with the  $\alpha$ -*AMA1* antibody, an additional co-localization assay was performed with an  $\alpha$ -*MSP1* antibody, as a marker for the merozoite surface. The results confirmed the merozoites surface-like staining of merozoites within the mature intact schizonts. To further evaluate the distribution of the different staining patterns, a total of 200 intact schizonts were assessed for the staining pattern; 99% ( $n = 198$ ) showed the *MSP1*-like staining with 1% showing a diffuse staining pattern. The apically concentrated staining pattern observed in released merozoites was observed in 99.5% of the evaluated merozoites ( $n = 995$ ) with the remaining 0.5% ( $n = 5$ ) showing a diffused staining pattern (summarized in **Figure 2D**). In addition, we examined purified schizont extracts from three laboratory isolates (3D7, W2mef, and Dd2) by Western blot analysis to determine the relative expression of *PfMAAP* protein in each isolate. Screening of the blots with the  $\alpha$ -*PfMAAP* antibody demonstrated that the protein





was expressed in each of the three isolates tested (Figure 3), which was in keeping with transcriptomic analysis reported in (23, 24) and on Plasmodb (<https://plasmodb.org/plasmo/>).


### Anti-PfMAAP Antibodies Inhibit Merozoite Invasion of Erythrocytes

To assess the potential functional importance of antibodies raised to the N- (*PfMAAP2* and 3) and C-terminal (*PfMAAP1*) domain peptides (Figure 1A), each antibody was assessed in a growth inhibition assay (GIA). Purified schizonts from three laboratory isolates (3D7, Dd2, and W2mef) were cultured with fresh red blood cells in the presence of the antigen-specific antibodies or the equivalent amounts of purified antibodies from pre-immune sera, in a dose dependent manner (0, 100, 250, and 500  $\mu\text{g/ml}$ ). Both  $\alpha$ -*PfMAAP1* (C-terminal) and  $\alpha$ -*PfMAAP2* (N-terminal)

inhibited parasite invasion of the Dd2 parasite strain by 15 and 25%, respectively at 0.5 mg/ml antibody concentration, whereas  $\alpha$ -*PfMAAP3* (N-terminal) inhibited parasite invasion of red blood cells by >60% at 0.5 mg/ml (Figure 4A). Similar levels of invasion inhibition were achieved for 3D7 (Figure 4B) and W2mef (Figure 4C), with the antibodies showing a dose dependent merozoites invasion inhibition.

### Antibodies Against PfMAAP Are Associated With Reduced Risk of Clinical Malaria

To investigate if *PfMAAP* might be a target of naturally acquired immunity, we expressed three recombinant proteins, based on the N- and C-terminal regions and the central polymorphic




repeat region of PfMAAP (Figure 1A). Each protein was expressed in *E. coli* as soluble GST-tagged fusion proteins and resolved on SDS-PAGE (Figure 5A). ELISA was performed on plasma samples collected in Chonyi village (33) to measure IgG reactivity against each antigen fragment. The antibody responses to each antigen fragment increased with age (Figure 5B). Interestingly, the highest responses were seen to the central repeat region (Figure 5B), which corresponds to the armadillo repeat region within PfMAAP. There was a reduction in the prospective risk of clinical malaria in the subsequent 6 months after plasma collection in Chonyi associated with antibodies to both the N- and C-terminal antigens (Table 1). Although this association was not seen to the central repeat armadillo region (Table 1).


## DISCUSSION

A critical step toward understanding the processes underlying parasite development, evasion of the immune system and the mechanisms involved in the selection and invasion of host cells, is understanding the role each protein plays in parasite biology. It is only through this that novel drug targets, diagnostics, or putative vaccine targets can be identified, and their role and relative importance be understood.

The armadillo super-repeat protein family appears to be involved in a variety of fundamental processes including cytoskeletal organization, cell-cell adhesion, organelle biogenesis,



and signaling. Despite the variety of functions associated with this protein family across a number of diverse species, the key aspect they share is the presence of the tandemly arranged armadillo repeats. Investigations into the role(s) of the armadillo repeat family of proteins play in the apicomplexa is still in its infancy but there is evidence about some of the essential roles this family of proteins play during parasite development (34). With their previously derived function in eukaryotic cells (26), identifying any additional family members in *Plasmodium* spp.



**FIGURE 5 |** PfMAAP antibodies are associated with naturally acquired immunity. **(A)** SDS PAGE showing the purified expressed and purified GST-tagged PfMAAP protein regions; N-term-GST, Central Repeat-GST, and C-term-GST. Antibody responses (OD) across all ages (October 2000) to the truncated PfMAAP recombinant antigens in **(B)** Chonyi ( $n = 518$ ). Age categories are as follows: 1 = 1–2 year,  $n = 54$ ; 2 = 3–4 year,  $n = 55$ ; 3 = 5–6 year,  $n = 55$ ; 4 = 7–8 year,  $n = 59$ ; 5 = 9–10 year,  $n = 59$ ; 6 = 11–15,  $n = 96$ ; 7 = 16–30  $n = 57$ ; 8 = 31–50,  $n = 56$ ; and 9 = 51–82,  $n = 27$ .

may illuminate different aspect of parasite biology with regards to interventions, potentially in the form of drugs, or vaccines.

To date, two armadillo repeat proteins have been described in *Plasmodium falciparum*. The *P. falciparum* armadillo-repeat only (PfARO), which bears similarity to  $\beta$ -catenin, an important cell-to-cell signaling molecule found in animals including humans (35). In *P. falciparum*  $\beta$ -catenin appears to be involved in both nuclear and rhoptry biogenesis (36). The homologous protein in *Toxoplasma gondii* (TgARO) is a multifunctional protein with similar functions to PfARO, such as rhoptry positioning and biogenesis. Importantly, TgARO can be functionally complemented by the orthologous

**TABLE 1 |** Association between the presence of serum IgG to the panel of 3 antigens in children aged <11 years and parasite slide positive in October 2000 in the Chonyi village, and the occurrence of malaria over the following 6 months.

Antigen	<sup>a</sup> Proportion of children acquiring malaria who were:		Univariate IRR (95% CI)	<sup>b</sup> Multivariate IRR (95% CI)	P
	IgG positive	IgG negative			
N-term	18% (7/39)	41% (33/80)	0.44 (0.21–0.90)	0.47 (0.25–0.89)	<b>0.021*</b>
Repeat	20% (10/49)	43% (30/70)	0.48 (0.26–0.88)	0.58 (0.31–1.04)	0.068
C-term	20% (8/40)	41% (32/79)	0.49 (0.25–0.97)	0.52 (0.28–0.93)	<b>0.028*</b>

<sup>c</sup>Chonyi village (<11 years and parasite slide positive  $n = 119$ )

Antigen	IgG positive	IgG negative	Univariate IRR (95% CI)	<sup>b</sup> Multivariate IRR (95% CI)	P
N-term	18% (7/39)	41% (33/80)	0.44 (0.21–0.90)	0.47 (0.25–0.89)	<b>0.021*</b>
Repeat	20% (10/49)	43% (30/70)	0.48 (0.26–0.88)	0.58 (0.31–1.04)	0.068
C-term	20% (8/40)	41% (32/79)	0.49 (0.25–0.97)	0.52 (0.28–0.93)	<b>0.028*</b>

CI, Confidence Interval; IRR, Incidence Risk Ratio.

<sup>a</sup>Number of individuals developing malaria/the total number of individuals that were IgG positive or negative.

<sup>b</sup>The Incidence Risk Ratio was estimated from multivariate analysis after adjusting for age and reactivity to *Plasmodium falciparum* schizont extract in a generalized linear models.

<sup>c</sup>Analysis focused on individuals who were parasitaemic at the time of serum sampling in October 2000.

\* $P < 0.05$ .

PfARO (37–39). The *P. falciparum* merozoite organizing protein (PfMOP), shown to localize to the inner membrane complex (IMC) and apical tip of the invasive merozoite stage of *P. falciparum*, appears to have a role in the biogenesis of the IMC as well as in rhoptry positioning (34, 36).

In this study we show the characterization of the PfMAAP protein, initially classified as the hypothetical protein, M566. The protein was also briefly assigned to the MSP3 family, but lacked the C-terminal domain that is a defining characteristic of the family (40). We demonstrate that the protein product is expressed around 40 h post invasion, which is supported by previously published microarray proteomic and transcriptomic data (24). In keeping with the *T. gondii* TgARO and the *P. falciparum* PfARO and PfMOP our results also show a clear association of PfMAAP with the mature schizont and free merozoites, particularly with the apical tip.

We also demonstrate a dual localization pattern, of a punctate apical staining profile and some merozoite surface staining. The dual localization pattern observed may be associated with the myriad of functions associated with this protein family and may also be due to the early release of the PfMAAP protein from the apical organelles. PfMAAP has a signal peptide but lacks a transmembrane domain or a GPI-anchor and based on existing literature and sequence interrogation of the proteins there appears to be no obvious PEXEL/HT motif (41, 42) or any features indicative of a PEXEL/HT negative exported protein (PNEP) (43). Gene deletion studies of the PfMAAP gene results in a reduction in growth (44) suggesting either a non-essential role in parasite development, functional redundancy or one that has a more pronounced effect elsewhere in the lifecycle.

Amino acid alignments of *P. falciparum* with available sequences for 6 non-human primate species (*Laverania* subgenus

of *Plasmodium*), including *P. praefalciparum* G01 and *P. reichenowi* CDC and G01, show high levels of sequence identity at both the N- and C-termini, including the signal peptide. This level of conservation suggests a possible evolutionarily conserved function for the PfMAAP protein that has yet to be defined.

Unlike the other Armadillo repeat containing genes described in *P. falciparum*, PfMAAP showed significant invasion inhibitory activity. Most importantly there was a statistically supported association between having antibody responses to the N- and C-terminal regions of PfMAAP and protection from malaria in Chonyi (22–53 infectious bites per year), although this association was not reflected in responses to the central repeat region. This difference in antibody responses to different parts of the same protein reflects what has been described for vaccine candidates and well-characterized markers of seroincidence in the same study sites, including MSP1 block 2, MSP1-19 and MSP2 (45, 46). The association between the conserved N- and C-terminal regions of PfMAAP with *in vitro* invasion inhibition, together with the cohort study analysis strongly suggests that this protein warrants further investigation as a potential target of naturally acquired immunity. Thus, understanding the role the PfMAAP protein plays in parasite biology may yield important targets for intervention strategies.

## MATERIALS AND METHODS

### Ethics Statement

Ethical approval for the use of the serum samples for use in this study had previously been obtained from the Kenyan National Ethics Committee, the University of Oxford, and the London School of Hygiene and Tropical Medicine as detailed in (47). Ethical approval for the Kenyan study on samples from human subjects was obtained from the Kenya National Research Ethics Committee, the University of Oxford, and the London School of Hygiene and Tropical Medicine. Written informed consent was obtained from a parent or guardian of each child contributing a blood sample and also from participating adults (47). Rabbit antibodies were obtained commercially by immunization under a commercial subcontract (Genscript). All animal work protocols were performed under the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International accreditation, following guidance written by the National Research Council of the U.S. National Academy of Sciences; and the Office for Animal Welfare (OLAW) certification, demonstrating an international commitment to responsible animal care and use.

### Parasite Cultures

*Plasmodium falciparum* laboratory isolates Dd2, W2mef, and 3D7 were cultured in complete RPMI-1640 (Sigma) (supplemented with 0.5% Albumax II (Gibco), 20 mg hypoxanthine, 2 g sodium bicarbonate (Sigma) and 0.05 mg/ml gentamicin sulfate (Sigma) using human group O<sup>+</sup> erythrocytes at 4% hematocrit in a mixed gas environment (93% nitrogen, 5% CO<sub>2</sub>, and 2% oxygen; Air Liquide, Birmingham, United Kingdom) at 37 °C. Merozoites were purified after allowing schizonts to burst in the absence of fresh erythrocytes

and pelleted at 4,000 rpm for 10 min. Parasite synchronizations were performed by treating mixed stages cultures with 5% D-Sorbitol (Sigma). Ring stages were then allowed to grow to schizonts. For tighter synchronizations, Percoll purified schizonts were allowed to invade over a 2-h period followed by Sorbitol treatment as describe above. For the time points, samples were collected every 8 h over a single cycle and stored in Trizol at –80°C freezer. RNA was extracted from each sample for subsequent gene expression analysis.

### Homology Modeling

A 3D predicted structural model of the full-length PfMAAP was obtained following submission to the I-TASSER server (<https://zhanglab.ccmb.med.umich.edu/I-TASSER/>) (29–31). The most robust model was further analyzed and edited using the PyMOL 2.2 software. Comparative analysis with known armadillo repeats proteins was performed using models submitted to the Protein Data Bank (PDB at <https://www.rcsb.org/>).

### Peptide Synthesis, Recombinant Proteins, and Polyclonal Antibody Generation

Three peptides (1-CQGEKVNKNDLNDAS, 2-FTENKEQKNEEVPVC, 3-VVNDGEEVKTEYVSC) were synthesized from the 3D7 amino acid template (Figure 1A) based on antigenicity, surface exposure and hydrophilicity scores (Genscript, US). Two of the peptides were located within the N-terminal region and the third within the C-terminal region, located in the Pumilio protein domain. Further validation of the synthesized peptide was performed by mass spectrometric analysis of the peptide sequences and HPLC analysis. Each peptide was injected at 200 µg/animal via the subcutaneous route (2 New Zealand Rabbits each) in Freund's complete/incomplete adjuvant using a customized 48 day immunization protocol (Genscript). A pre-bleed sample was taken at day–4, with the primary immunization delivered on day 0. Booster immunisations were given on days 14 and 35, test bleeds were taken on days 21 and 42, with the protocol completed on day 48. Polyclonal antibodies were purified from the pooled sera for each of the peptides, and confirmed by ELISA titrations to a dilution limit of 1:512,000 (1.95 ng/ml). Antibodies were purified over a bed of protein A/G coupled beads and concentrated (Using Amicon 30 kDa, Merck) or diluted to the required concentration for use in the different assays they were intended.

In addition, three recombinant proteins were designed and expressed in *E. coli* as GST-tagged fusion proteins, targeting the N-, central polymorphic repeat and C-terminal regions (Figure 1A). The N- (nt 67-429) and C-terminal (nt 1513-1698) regions, both showing minimal polymorphism, and the polymorphic central repeat region (nt 430-1512) were PCR amplified from 3D7 genomic DNA. The sequence validated amplified inserts were cloned into the pGEX-2T expression vector (GE Healthcare) followed by additional sequence verification prior to transformation and expression in BL21 (DE3) *E. coli*. Expression and affinity purification were performed as described previously for other GST-fusion proteins (47).



Purified proteins were assessed for purity and integrity by SDS PAGE (Figure 5A).

## Immunofluorescent Assays and Microscopy

The Protein A/G-affinity purified antibodies raised to the peptide fragments were assessed for reactivity to native parasite proteins by IFA. Synchronized late stage schizonts were smeared, air-dried and fixed with acetone (Merck) for 5 min at RT. The slides were co-incubated with rabbit anti-PfMAAP antibodies (PfMAAP 1-3) (1:500) and either anti-mouse PfAMA1 (1:1,000) (MR4),  $\alpha$ -PfRAP2 (1:1,000),  $\alpha$ -PfRON4 (1:400),  $\alpha$ -PfMSP1 or  $\alpha$ -PfGAP45, respectively, for 1 h in 3% BSA/PBS buffer, followed by three washes in 1X PBS at 5 min/wash. The slides were then incubated with Alexa Flour 594 goat anti-mouse IgG (H+L) (red) and Alexa Flour 488 goat anti-rabbit IgG (H+L) (red) secondary antibodies (1:1,000 respectively) (Molecular Probes) for 1 h. Slides were washed in 1X PBS three times for 5 min each and air-dried. Mounting medium containing DAPI (Vector laboratories) was added to each slide and sealed with a coverslip for microscopy. The cells were imaged on an Olympus System Microscope Model BX41 with a Hamamatsu ORCA-spark Digital CMOS camera C11440-36U. In total 50 images were taken for each antibody used. All image background subtraction, brightness and contrast adjustment as well as all analysis were conducted using Fiji ImageJ software.

## Western Blot Analysis of Parasite Extracts and Culture Supernatants

Ring stage cultures were synchronized with 5% D-sorbitol (Sigma) and cultured to mature stage schizonts (48, 49), followed by purification over a Percoll gradient (50). The purified schizonts were washed twice with 1xPBS and resuspended in 1xPBS. Aliquots were lysed in SDS PAGE sample buffer, resolved using a 12% SDS-PAGE before transfer onto nitrocellulose membranes (0.2  $\mu$ m, Bio-Rad). Proteins were detected using the PfMAAP1 & 2 polyclonal antibodies (pAbs) @ 1:1,000 dilution. Following primary incubation, the blots were washed and incubated with anti-rabbit HRP-conjugated secondary antibodies @ 1:3,000 dilution for 1 h followed by two washes with 1X PBS. The membrane was developed using enhanced chemiluminescence (GE healthcare) and developed using the KODAK image analysis system.

## Merozoites Invasion Inhibition Assay

Synchronized late-stage schizonts were purified, and assays were plated as previously described (50). Briefly, target cells (erythrocyte acceptor cells) were stained with 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester at 20  $\mu$ M (5(6)CFDA-SE; Invitrogen), a cytoplasmic fluorescent stain, to help differentiate erythrocytes invaded in the assay from those in the parasite inoculum. Late stage parasites at 2% parasitemia were mixed with the 5(6)CFDA-SE-labeled erythrocyte acceptor cells in a 1:1 ratio at 2% hematocrit in 100  $\mu$ l assays in 96-well titer plates. Increasing concentrations of purified anti-peptide antibody for PfMAAP peptides 1- 3 (0–500  $\mu$ g/ml) were added

to corresponding wells. Control wells were incubated with pre-immune sera. Assays plates were incubated overnight at 37°C in a mixed gas environment to allow one cycle of invasion. Cells were stained with Hoechst 33342 (Sigma Aldrich) and washed 3 times with complete RPMI. Invaded target cells were counted with a BD LSR Fortessa X20 flow cytometer. The experiment was run twice independently with each condition conducted in triplicate. A total of 50,000 RBCs were counted and % invasion into the 5(6)CFDA-SE-labeled target cells were recorded. The percentage of successfully invaded RBCs in the presence of anti-PfMAAP antibodies or the pre-immune controls were compared with the level of invasion in control wells without antibody added.

## Expression Levels of PfMAAP

The expression of the PfMAAP were assayed in three laboratory isolates (3D7, Dd2 and W2mef), following 6, 8-h sample collection time points. The expression analysis assay protocol was as described by Baker et al. (51). Briefly, RNA was purified from tightly synchronized parasites as described previously, using the AllPrep DNA/RNA Mini kit protocol by Qiagen (Qiagen, Germany) and treated with DNase to remove all traces of DNA in the sample. The cDNA synthesis was then carried out with a control reaction (without a reverse transcriptase) using the Superscript III first-strand protocol following manufacturer's instructions (ThermoFisher Scientific, USA). The cDNA synthesis reaction conditions were as follows: 25°C for 10 min, 50°C for 50 min and 85°C for 5 min. Following the cDNA synthesis, 1  $\mu$ l of RNase H was added to each reaction, mixed and incubated at 37°C for 20 min followed by 95°C for 10 min to remove unconverted RNA molecules. The quantitation of the transcript level of PfMAAP gene was evaluated relative to the 60S ribosomal protein L18-2 (PF3D7\_1341300) (51); a housekeeping gene used as a control. Each experiment was conducted in triplicate and conducted at two independent times. The expression levels were calculated from the Ct values using the  $2^{-\Delta\Delta Ct}$  formula.

## Analysis of Naturally Acquired Antibodies

The plasma samples analyzed in the study were previously collected as part of a community cohort study undertaken in Chonyi, Kenya. A village in Kilifi district near the eastern coast of Kenya. The inhabitants were naturally exposed to biannual peaks of transmission in November to December and May to July, with moderate rates of transmission at the time of sampling (22–53 infectious bites/person/year; October 2000) (33). Active and passive case detection was used to determine the occurrence of episodes of clinical malaria in the following 6-month period within the communities. Indirect ELISAs were performed with each of the three antigens using protocols as previously described (47). Briefly, antigens coated at 50 ng/well were in duplicate with sera diluted to 1/500. Due to the fact that the proteins used in the assay were generated as GST-tagged fusion proteins, purified GST was included in the assay and results subtracted to correct for any background reactivity to the tag. Samples were scored as positive if the ELISA optical density (OD) values were higher than the mean plus 3 standard deviations of the values from 20 malaria-naive control sera tested in parallel (the same panel of

negative-control sera was used in all assays). The risk of clinical malaria and association with antibody status was analyzed for subjects who were asymptomatic and <11 years of age at the time of sampling (Chonyi N=119/518), as done previously in analyses of antibodies to other antigens (47).

## Data Analysis

Boxplots were generated in R (R studio, version 3.5.2). Generalized linear models (GLM) were used to determine the risk ratio (RR) associated with the presence or absence of detectable serum antibodies (IgG above the cut-off OD value) and the occurrence of subsequent clinical malaria episodes. Age and antibody reactivity to parasite schizont extract were used in multivariate analyses to correct for the confounding effects of exposure on antibody responses. Statistical analyses were performed using Stata/IC (StataCorp LP, USA).

## DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/[Supplementary Material](#).

## AUTHOR CONTRIBUTIONS

YA, GA, and KT: conceptualization. YA, GA, KT, DC, and FO: designed experiments. YA, PN, EC-C, FA, EQ, GK, LT, and KT: performed experiments. YA, KT, PN, and FA: analyzed the data. KT, GA, DC, and KM: supervised the study. YA, KT, GA, and DC: wrote the manuscript. All authors read and agreed to the final manuscript.

## FUNDING

This work was supported with funds from a Wellcome/African Academy of Sciences of DELTAS Africa, World Bank African Centers of Excellence (ACE02-WACCBIP: Awandare) grant (DEL-15-007: Awandare) and a Q7 the National Institute for Health Research, using Official Development Assistance (ODA) funding (16/136/33: Woolhouse). The funders had no role in the conception, study design, data collection and analysis, decision to publish or preparation of the manuscript. YA was supported by a WACCBIP DELTAS Masters fellowship, while EQ was supported

by WACCBIP DELTAS Postdoctoral fellowship to YA. PN, EC-C, and LT are supported by WACCBIP ACE PhD and Master's fellowships. FA was supported by the Tackling Infections to Benefit Africa (TIBA) partnership under a National Institute of Health Research Global Health Research Unit grant to University of Edinburgh.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2020.00505/full#supplementary-material>

**Figure S1** | Amino acid sequence alignment of full-length sequences from 16 *Plasmodium falciparum* isolates for PfMAAP (PF3D7\_1035900, PfSD01\_100040400, PfML01\_100039900, PfKE01\_100041100, PfIT\_100039800, PfGB4\_100040700, PfGN01\_100041300, PfTG01\_100041000, PfDd2\_100041100, PfSN01\_100041200, PfKH02\_100041200, Pf7G8\_100040200, PfHB3\_100040200, PfGA01\_100041100, PfKH01\_100040300, PfCD01\_100041000). Alignments were generated using Clustal Omega (Sievers et al., 2011). All sequences were obtained from Plasmodb (<https://plasmodb.org/plasmo/>).

**Figure S2** | Amino acid alignment of full-length sequences from non-malaria isolates for PfMAAP (PF3D7\_1035900) aligned with the 3D7 isolate as a reference. Alignments were generated using Clustal Omega (Sievers et al., 2011). *Plasmodium falciparum*, PF3D7\_1035900; *Plasmodium rechenowi*, PRG01\_1034400 and PRCDC\_1035200; *Plasmodium billcollinsi*, PBILCG01\_1034800; *Plasmodium gaboni*, PGSY75\_0012400; *Plasmodium praefalciparum*, PPRFG01\_1036900; and *Plasmodium adleri*, PADL01\_1034600. All sequences were obtained from Plasmodb (<https://plasmodb.org/plasmo/>).

**Figure S3** | N- and C-terminal semi-conserved and armadillo repeat sequences for PfMAAP in (A) sixteen laboratory adapted isolates (PF3D7\_1035900, PfSD01\_100040400, PfML01\_100039900, PfKE01\_100041100, PfIT\_100039800, PfGB4\_100040700, PfGN01\_100041300, PfTG01\_100041000, PfDd2\_100041100, PfSN01\_100041200, PfKH02\_100041200, Pf7G8\_100040200, PfHB3\_100040200, PfGA01\_100041100, PfKH01\_100040300, PfCD01\_100041000) and (B) in five *Laverania* subgenus of *Plasmodium* (*P.rechenowi*, PRG01\_1034400 and PRCDC\_1035200; *P.billcollinsi*, PBILCG01\_1034800; *P.gaboni*, PGSY75\_0012400; *P.praefalciparum*, PPRFG01\_1036900; and *P.adleri*, PADL01\_1034600). All sequences were obtained from Plasmodb (<https://plasmodb.org/plasmo/>).

**Figure S4** | Co-localization of  $\alpha$ -PfMAAP1 and 2 with  $\alpha$ -AMA1. (A) PfMAAP1 (green) localization pattern relative to PfAMA1 (red) with DAPI (blue) staining for nuclei and the merging of all channels (Merge). (B) PfMAAP2 (green) co-localization with PfAMA1 (red) with DAPI (blue) staining the nuclei and the merge of all channels (Merge). Fifty images were taken per antibody tested using an Olympus model BX41 fluorescent microscope with a x100 oil-immersion objective.

## REFERENCES

- Cowman AE, Tonkin CJ, Tham WH, Duraisingh MT. The molecular basis of erythrocyte invasion by malaria parasites. *Cell Host Microbe*. (2017) 22:232–45. doi: 10.1016/j.chom.2017.07.003
- Wright GJ, Rayner JC. *Plasmodium falciparum* erythrocyte invasion: combining function with immune evasion. *PLoS Pathog*. (2014) 10:e1003943. doi: 10.1371/journal.ppat.1003943
- Aniweh Y, Gao X, Gunalan K, Preiser PR. PfRH2b specific monoclonal antibodies inhibit merozoite invasion. *Mol Microbiol*. (2016) 102:386–404. doi: 10.1111/mmi.13468
- Baum J, Chen L, Healer J, Lopatnicki S, Boyle M, Triglia T, et al. Reticulocyte-binding protein homologue 5 - an essential adhesin involved in invasion of human erythrocytes by *Plasmodium falciparum*. *Int J Parasitol*. (2009) 39:371–80. doi: 10.1016/j.ijpara.2008.10.006
- Gunalan K, Gao X, Liew KJ, Preiser PR. Differences in erythrocyte receptor specificity of different parts of the *Plasmodium falciparum* reticulocyte binding protein homologue 2a. *Infect Immun*. (2011) 79:3421–30. doi: 10.1128/IAI.00201-11
- Rayner JC, Galinski MR, Ingrassia P, Barnwell JW. Two *Plasmodium falciparum* genes express merozoite proteins that are related to *Plasmodium vivax* and *Plasmodium yoelii* adhesive proteins involved in host cell selection and invasion. *Proc Natl Acad Sci USA*. (2000) 97:9648–53. doi: 10.1073/pnas.160469097
- Rayner JC, Vargas-Serrato E, Huber CS, Galinski MR, Barnwell JW. A *Plasmodium falciparum* homologue of *Plasmodium vivax* reticulocyte binding protein. (PvRBP1) defines a trypsin-resistant erythrocyte invasion pathway. *J Exp Med*. (2001) 194:1571–81. doi: 10.1084/jem.194.11.1571
- Tham WH, Wilson DW, Reiling L, Chen L, Beeson JG, Cowman AF. Antibodies to reticulocyte binding protein-like homologue 4 inhibit invasion

- of *Plasmodium falciparum* into human erythrocytes. *Infect Immun.* (2009) 77:2427–35. doi: 10.1128/IAI.00048-09
9. Dolan SA, Proctor JL, Alling DW, Okubo Y, Wellem TE, Miller LH. Glycophorin B as an EBA-175 independent *Plasmodium falciparum* receptor of human erythrocytes. *Mol Biochem Parasitol.* (1994) 64:55–63. doi: 10.1016/0166-6851(94)90134-1
  10. Lobo CA, Rodriguez M, Reid M, Lustigman S. Glycophorin C is the receptor for the *Plasmodium falciparum* erythrocyte binding ligand PfEBP-2. (baebl). *Blood.* (2003) 101:4628–31. doi: 10.1182/blood-2002-10-3076
  11. Mayer DC, Mu JB, Feng X, Su XZ, Miller LH. Polymorphism in a *Plasmodium falciparum* erythrocyte-binding ligand changes its receptor specificity. *J Exp Med.* (2002) 196:1523–8. doi: 10.1084/jem.20020750
  12. Michon P, Stevens JR, Kaneko O, Adams JH. Evolutionary relationships of conserved cysteine-rich motifs in adhesive molecules of malaria parasites. *Mol Biol Evol.* (2002) 19:1128–42. doi: 10.1093/oxfordjournals.molbev.a004171
  13. Persson KE, Fowkes FJ, Mccallum FJ, Gicheru N, Reiling L, Richards JS, et al. Erythrocyte-binding antigens of *Plasmodium falciparum* are targets of human inhibitory antibodies and function to evade naturally acquired immunity. *J Immunol.* (2013) 191:785–94. doi: 10.4049/jimmunol.1300444
  14. Peterson DS, Wellem TE. EBL-1, a putative erythrocyte binding protein of *Plasmodium falciparum*, maps within a favored linkage group in two genetic crosses. *Mol Biochem Parasitol.* (2000) 105:105–13. doi: 10.1016/S0166-6851(99)00173-5
  15. Cao J, Kaneko O, Thongkukiatkul A, Tachibana M, Otsuki H, Gao Q, et al. Rhoptry neck protein RON2 forms a complex with microneme protein AMA1 in *Plasmodium falciparum* merozoites. *Parasitol Int.* (2009) 58:29–35. doi: 10.1016/j.parint.2008.09.005
  16. Proellocks NI, Coppel RL, Waller KL. Dissecting the apicomplexan rhoptry neck proteins. *Trends Parasitol.* (2010) 26:297–304. doi: 10.1016/j.pt.2010.02.012
  17. Collins CR, Withers-Martinez C, Hackett F, Blackman MJ. An inhibitory antibody blocks interactions between components of the malarial invasion machinery. *PLoS Pathog.* (2009) 5:e1000273. doi: 10.1371/journal.ppat.1000273
  18. Mbengue B, Fall MM, Varela ML, Loucoubar C, Joos C, Fall B, et al. Analysis of antibody responses to selected *Plasmodium falciparum* merozoite surface antigens in mild and cerebral malaria and associations with clinical outcomes. *Clin Exp Immunol.* (2019) 196:86–96. doi: 10.1111/cei.13254
  19. Amambua-Ngwa A, Tetteh KK, Manske M, Gomez-Escobar N, Stewart LB, Deerrhake ME, et al. Population genomic scan for candidate signatures of balancing selection to guide antigen characterization in malaria parasites. *PLoS Genet.* (2012) 8:e1002992. doi: 10.1371/journal.pgen.1002992
  20. Kana IH, Singh SK, Garcia-Senosai A, Dodoo D, Singh S, Adu B, et al. Breadth of functional antibodies is associated with *Plasmodium falciparum* merozoite phagocytosis and protection against febrile malaria. *J Infect Dis.* (2019) 220:275–84. doi: 10.1093/infdis/jiz088
  21. Kana IH, Garcia-Senosai A, Singh SK, Tiendrebeogo RW, Chourasia BK, Malhotra P, et al. Cytophilic antibodies against key *Plasmodium falciparum* blood stage antigens contribute to protection against clinical malaria in a high transmission region of Eastern India. *J Infect Dis.* (2018) 218:956–65. doi: 10.1093/infdis/jiy258
  22. Seck MC, Thwing J, Badiane AS, Rogier E, Fall FB, Ndiaye PI, et al. Analysis of anti-*Plasmodium* IgG profiles among Fulani nomadic pastoralists in northern Senegal to assess malaria exposure. *Malar J.* (2020) 19:15. doi: 10.1186/s12936-020-3114-2
  23. Llinas M, Bozdech Z, Wong ED, Adai AT, Derisi JL. Comparative whole genome transcriptome analysis of three *Plasmodium falciparum* strains. *Nucleic Acids Res.* (2006) 34:1166–73. doi: 10.1093/nar/gkj517
  24. Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, Derisi JL. The transcriptome of the intraerythrocytic developmental cycle of *Plasmodium falciparum*. *PLoS Biol.* (2003) 1:E5. doi: 10.1371/journal.pbio.000005
  25. Coates JC. Armadillo repeat proteins: beyond the animal kingdom. *Trends Cell Biol.* (2003) 13:463–71. doi: 10.1016/S0962-8924(03)00167-3
  26. Tewari R, Bailes E, Bunting KA, Coates JC. Armadillo-repeat protein functions: questions for little creatures. *Trends Cell Biol.* (2010) 20:470–81. doi: 10.1016/j.tcb.2010.05.003
  27. Gruber M, Söding J, Lupas AN. REPPER—repeats and their periodicities in fibrous proteins. *Nucleic Acids Res.* (2005) 33:W239–43. doi: 10.1093/nar/gki405
  28. Zimmermann L, Stephens A, Nam SZ, Rau D, Kubler J, Lozajic M, et al. A completely reimplemented MPI bioinformatics toolkit with a new hhpred server at its core. *J Mol Biol.* (2018) 430:2237–43. doi: 10.1016/j.jmb.2017.12.007
  29. Zhang Y. I-TASSER server for protein 3D structure prediction. *BMC Bioinform.* (2008) 9:40. doi: 10.1186/1471-2105-9-40
  30. Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER Suite: protein structure and function prediction. *Nat Methods.* (2015) 12:7–8. doi: 10.1038/nmeth.3213
  31. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. *Nat Protoc.* (2010) 5:725–38. doi: 10.1038/nprot.2010.5
  32. Meerstein-Kessel L, Van Der Lee R, Stone W, Lanke K, Baker DA, Alano P, et al. Probabilistic data integration identifies reliable gametocyte-specific proteins and transcripts in malaria parasites. *Sci Rep.* (2018) 8:410. doi: 10.1038/s41598-017-18840-7
  33. Mwangi TW, Ross A, Snow RW, Marsh K. Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. *J Infect Dis.* (2005) 191:1932–9. doi: 10.1086/430006
  34. Absalon S, Robbins JA, Dvorin JD. An essential malaria protein defines the architecture of blood-stage and transmission-stage parasites. *Nat Commun.* (2016) 7:11449. doi: 10.1038/ncomms11449
  35. Nakamura Y, Hoppler S. Genome-wide analysis of canonical Wnt target gene regulation in *Xenopus tropicalis* challenges  $\beta$ -catenin paradigm. *Genesis.* (2017) 55:e22991. doi: 10.1002/dvg.22991
  36. Mitra P, Gupta ED, Sahar T, Pandey AK, Dangi P, Reddy KS, et al. Evidence for the nucleolar-shuttling of a beta-catenin like *Plasmodium falciparum* armadillo repeat containing protein. *PLoS ONE.* (2016) 11:e0148446. doi: 10.1371/journal.pone.0148446
  37. Beck JR, Fung C, Straub KW, Coppens I, Vashisht AA, Wohlschlegel JA, et al. A Toxoplasma palmitoyl acyl transferase and the palmitoylated armadillo repeat protein TgARO govern apical rhoptry tethering and reveal a critical role for the rhoptries in host cell invasion but not egress. *PLoS Pathog.* (2013) 9:e1003162. doi: 10.1371/journal.ppat.1003162
  38. Cabrera A, Herrmann S, Warszta D, Santos JM, John Peter AT, Kono M, et al. Dissection of minimal sequence requirements for rhoptry membrane targeting in the malaria parasite. *Traffic.* (2012) 13:1335–50. doi: 10.1111/j.1600-0854.2012.01394.x
  39. Mueller C, Klages N, Jacot D, Santos JM, Cabrera A, Gilberger TW, et al. The Toxoplasma protein ARO mediates the apical positioning of rhoptry organelles, a prerequisite for host cell invasion. *Cell Host Microbe.* (2013) 13:289–301. doi: 10.1016/j.chom.2013.02.001
  40. Singh S, Soe S, Weisman S, Barnwell JW, Perignon JL, Druilhe P. A conserved multi-gene family induces cross-reactive antibodies effective in defense against *Plasmodium falciparum*. *PLoS ONE.* (2009) 4:e5410. doi: 10.1371/journal.pone.0005410
  41. Marti M, Good RT, Rug M, Knuepfer E, Cowman AF. Targeting malaria virulence and remodeling proteins to the host erythrocyte. *Science.* (2004) 306:1930–3. doi: 10.1126/science.1102452
  42. Hiller NL, Bhattacharjee S, Van Ooij C, Liolios K, Harrison T, Lopez-Estrano C, et al. A host-targeting signal in virulence proteins reveals a secretome in malarial infection. *Science.* (2004) 306:1934–7. doi: 10.1126/science.1102737
  43. Heiber A, Kruse F, Pick C, Gruring C, Flemming S, Oberli A, et al. Identification of new PNEPs indicates a substantial non-PEXEL exportome and underpins common features in *Plasmodium falciparum* protein export. *PLoS Pathog.* (2013) 9:e1003546. doi: 10.1371/journal.ppat.1003546
  44. Zhang M, Wang C, Otto TD, Oberstaller J, Liao X, Adapa SR, et al. Uncovering the essential genes of the human malaria parasite *Plasmodium falciparum* by saturation mutagenesis. *Science.* (2018) 360:eap7847. doi: 10.1126/science.aap7847
  45. Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Williams TN, et al. High levels of serum antibodies to merozoite surface protein 2 of

- Plasmodium falciparum* are associated with reduced risk of clinical malaria in coastal Kenya. *Vaccine*. (2006) 24:4233–46. doi: 10.1016/j.vaccine.2005.06.030
46. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KK, et al. Breadth and magnitude of antibody responses to multiple *Plasmodium falciparum* merozoite antigens are associated with protection from clinical malaria. *Infect Immun*. (2008) 76:2240–8. doi: 10.1128/IAI.01585-07
  47. Tetteh KK, Osier FH, Salanti A, Kamuyu G, Drought L, Faily M, et al. Analysis of antibodies to newly described *Plasmodium falciparum* merozoite antigens supports MSPDBL2 as a predicted target of naturally acquired immunity. *Infect Immun*. (2013) 81:3835–42. doi: 10.1128/IAI.00301-13
  48. Lambros C, Vanderberg JP. Synchronization of *Plasmodium falciparum* erythrocytic stages in culture. *J Parasitol*. (1979) 418–20. doi: 10.2307/3280287
  49. Miao J, Cui L. Rapid isolation of single malaria parasite-infected red blood cells by cell sorting. *Nat Protocols*. (2011) 6:140. doi: 10.1038/nprot.2010.185
  50. Awandare GA, Nyarko PB, Aniweh Y, Ayivor-Djanie R, Stoute JA. *Plasmodium falciparum* strains spontaneously switch invasion phenotype in suspension culture. *Sci Rep*. (2018) 8:5782. doi: 10.1038/s41598-018-24218-0
  51. Baker J, Gatton ML, Peters J, Ho MF, McCarthy JS, Cheng Q. Transcription and expression of *Plasmodium falciparum* histidine-rich proteins in different stages and strains: implications for rapid diagnostic tests. *PLoS ONE*. (2011) 6:e22593. doi: 10.1371/journal.pone.0022593
- Disclaimer:** The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health, World Bank or Wellcome Trust.
- Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- The reviewer LK declared a shared affiliation, with no collaboration, with one of the authors, KM, to the handling editor at the time of the review.
- Copyright © 2020 Aniweh, Nyarko, Charles-Chess, Ansah, Osier, Quansah, Thiam, Kamuyu, Marsh, Conway, Tetteh and Awandare. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.